Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dasatinib - Xspray Pharma

Next Previous
X
Search
Drug Profile

Dasatinib - Xspray Pharma

Alternative Names: Dasynoc; HyNap-Dasa; XS-004

Latest Information Update: 24 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xspray Pharma
  • Class Amides; Antineoplastics; Chlorobenzenes; Piperazines; Pyrimidines; Small molecules; Thiadiazoles; Thiazoles
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Bcr-Abl tyrosine kinase modulators; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Src-family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 19 Sep 2024 Xspray Pharma plans to launch dasatinib in Q1 of 2025 in the US
  • 19 Sep 2024 Xspray Pharma announces intention to resubmit NDA to US FDA for Precursor cell lymphoblastic leukemia-lymphoma and Chronic myeloid leukemia in Q4 of 2024
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia(In volunteers) in India (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top